Hikma Pharmaceuticals plc

Previously facing the prospect of a jury trial beginning next month, Jazz Pharmaceuticals has agreed in principle to pay $145m to resolve certain allegations that its US patent-litigation settlement a

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. B+L Bolsters Ophthalmology With Acquis

Hikma’s CEO Riad Mishlawi must have been on a good list as his wish to get US approval for the firm’s generic liraglutide around Christmas came true. The US Food and Drug Administration approved the g

In its latest effort to identify drugs with price increases that had the biggest impact on US health care spending, the Institute for Clinical and Economic Review (ICER) included Merck & Co.’s Key